State Key Laboratory of Reproductive Medicine, Department of Clinic Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application, NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, Xuzhou Medical University, Xuzhou 221004, China.
Science. 2022 Oct 28;378(6618):390-398. doi: 10.1126/science.abo3566. Epub 2022 Oct 27.
Major depressive disorder (MDD) is one of the most common mental disorders. We designed a fast-onset antidepressant that works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). Chronic unpredictable mild stress (CMS) selectively increased the SERT-nNOS complex in the DRN in mice. Augmentation of SERT-nNOS interactions in the DRN caused a depression-like phenotype and accounted for the CMS-induced depressive behaviors. Disrupting the SERT-nNOS interaction produced a fast-onset antidepressant effect by enhancing serotonin signaling in forebrain circuits. We discovered a small-molecule compound, ZZL-7, that elicited an antidepressant effect 2 hours after treatment without undesirable side effects. This compound, or analogous reagents, may serve as a new, rapidly acting treatment for MDD.
重度抑郁症(MDD)是最常见的精神障碍之一。我们设计了一种快速起效的抗抑郁药,其作用机制是破坏背缝核(DRN)中血清素转运蛋白(SERT)和神经元型一氧化氮合酶(nNOS)之间的相互作用。慢性不可预测轻度应激(CMS)选择性地增加了 DRN 中的 SERT-nNOS 复合物。DRN 中 SERT-nNOS 相互作用的增强导致了类似抑郁的表型,并解释了 CMS 诱导的抑郁行为。破坏 SERT-nNOS 相互作用通过增强前脑回路中的血清素信号产生了快速起效的抗抑郁作用。我们发现了一种小分子化合物 ZZL-7,它在治疗后 2 小时内产生抗抑郁作用,而没有不良副作用。这种化合物或类似的试剂可能成为治疗 MDD 的一种新的、快速作用的治疗方法。